Cargando…
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation
BACKGROUND: Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In clinical trials, the most common adverse events observed were nasopharyngitis, upper respiratory tract infections, and zoster. JAKs are...
Autores principales: | Hawerkamp, Heike C., Domdey, Alina, Radau, Lisa, Sewerin, Philipp, Oláh, Péter, Homey, Bernhard, Meller, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138978/ https://www.ncbi.nlm.nih.gov/pubmed/34020693 http://dx.doi.org/10.1186/s13075-021-02509-8 |
Ejemplares similares
-
Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea
por: Mylonas, Alessio, et al.
Publicado: (2023) -
The Endogenous Dual Retinoid Receptor Agonist Alitretinoin Exhibits Immunoregulatory Functions on Antigen-Presenting Cells
por: Kislat, Andreas, et al.
Publicado: (2023) -
Interleukin-26 activates macrophages and facilitates killing of Mycobacterium tuberculosis
por: Hawerkamp, Heike C., et al.
Publicado: (2020) -
Antiviral Host Defence Peptides
por: Sousa, Filipa Henderson, et al.
Publicado: (2016) -
Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis
por: Hawerkamp, H. C., et al.
Publicado: (2022)